Pennsylvania biotech Ocugen has raised $7.5 million in a series B round as it fixes its sights on advancing a trio of eye disease treatments into clinical trials. The new fundraising will help fund additional testing of Ocugen's lead candidate OCU300 for ocular graft-versus-host disease (GVHD)—which has no approved therapies in the U.S.—and help bring two preclinical candidates for retinitis pigmentosa (OCU100) and wet age-related macular degeneration (OCU200) into the clinic for the first time.